Equities Analysts Issue Forecasts for Genelux Q3 Earnings

Genelux Corporation (NASDAQ:GNLX) – Brookline Capital Markets boosted their Q3 2026 EPS estimates for shares of Genelux in a research report issued to clients and investors on Monday, August 17th. Brookline Capital Markets analyst K. Dolliver now anticipates that the company will post earnings per share of ($0.19) for the quarter, up from their previous estimate of ($0.20). The consensus estimate for Genelux’s current full-year earnings is ($0.80) per share. Brookline Capital Markets also issued estimates for Genelux’s Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.80) EPS and FY2027 earnings at ($0.59) EPS.

Genelux (NASDAQ:GNLX) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01).

Several other analysts also recently weighed in on the stock. Benchmark reissued a “speculative buy” rating on shares of Genelux in a research note on Tuesday. Wall Street Zen lowered Genelux from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genelux in a research report on Friday, July 17th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Genelux has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Genelux Price Performance

NASDAQ:GNLX opened at $2.68 on Thursday. The company has a market capitalization of $121.24 million, a price-to-earnings ratio of -3.12 and a beta of 0.60. Genelux has a 1-year low of $2.29 and a 1-year high of $8.53. The business has a 50 day moving average of $2.87 and a 200 day moving average of $2.77.

Insiders Place Their Bets

In related news, Director John W. Smither sold 12,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $2.91, for a total value of $34,920.00. Following the transaction, the director owned 91,403 shares of the company’s stock, valued at approximately $265,982.73. This trade represents a 11.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director John Thomas sold 10,000 shares of Genelux stock in a transaction on Monday, June 1st. The stock was sold at an average price of $2.98, for a total transaction of $29,800.00. Following the transaction, the director owned 472,784 shares in the company, valued at $1,408,896.32. This represents a 2.07% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 25,868 shares of company stock valued at $76,120. Company insiders own 7.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. purchased a new position in Genelux during the first quarter valued at approximately $239,000. Jane Street Group LLC bought a new stake in shares of Genelux in the first quarter worth about $190,000. Geode Capital Management LLC increased its stake in Genelux by 1.8% in the 2nd quarter. Geode Capital Management LLC now owns 318,825 shares of the company’s stock worth $915,000 after acquiring an additional 5,596 shares during the last quarter. Marshall Wace LLP purchased a new stake in Genelux during the second quarter valued at $92,000. Finally, Raymond James Financial Inc. raised its position in shares of Genelux by 22.6% during the 2nd quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock valued at $83,000 after buying an additional 5,333 shares in the last quarter. 37.33% of the stock is owned by hedge funds and other institutional investors.

Genelux News Roundup

Here are the key news stories impacting Genelux this week:

• Positive Sentiment: HC Wainwright modestly improved its Q4 2026 EPS forecast to a loss of $0.19 from a loss of $0.20. The firm also continues to project a potential transition to profitability, forecasting positive EPS of $0.61 in FY2028, $1.63 in FY2029 and $2.52 in FY2030.
• Neutral Sentiment: Brookline Capital Markets initiated quarterly FY2027 estimates ranging from a $0.10 loss per share in Q1 to a $0.19 loss in Q4. These projections indicate that Genelux is expected to remain unprofitable throughout FY2027, broadly consistent with the company’s development-stage profile and the current full-year consensus estimate of a $0.80 loss per share.
• Negative Sentiment: HC Wainwright lowered its FY2027 EPS forecast to a $0.77 loss from a $0.75 loss and reduced its Q3 2026 estimate to a $0.21 loss from a $0.20 loss. It also cut its long-term estimates for FY2028, FY2029 and FY2030 to $0.61, $1.63 and $2.52 per share, respectively, from $0.64, $1.69 and $2.61.

Genelux Company Profile

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.